Pfizer Announces Overall Survival Results from Phase 3 PALOM

Pfizer Inc. today announced overall survival results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® in combination with letrozole compared to placebo plus letrozole for the... | June 4, 2022

Related Keywords

United States , New York , American , Richard Finn , Chris Boshoff , World Evidence Program , American Society Of Clinical Oncology , Linkedin , David Geffen School Of Medicine , Jonsson Comprehensive Cancer Center , Pfizer Global Product Development , Exchange Commission , Pfizer , Youtube , Pfizer Inc , Hazard Ratio , American Society , Clinical Oncology , Chief Development Officer , Pfizer Global Product , Geffen School , Jonsson Comprehensive Cancer , Disease Free Interval , New England Journal , World Evidence , Pfizer Oncology , Breakthroughs That Change Patient , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future , Pfizer Data , Cell Cycle , Garland Science , Cycle Deregulation , Humana Press , Nc Stock Exchange , News , Information , Press Release , Oday , Nnounced , Verall , Survival , Results , Rom , The , Hase , , Which , Revaluated , N , Combination , Ith , Letrozole , Ompared , O , Placebo , Plus , Or Pfe Us7170811035 ,